Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain
- Published on 01/31/2025
- Reading time: 6 min.
Iftimie Simona 1, Ladero-Palacio Paula 1, López-Azcona Ana F. 1, Pujol-Galarza Laia 2, Pont-Salvadó Antoni 2, Gabaldó-Barrios Xavier 3, Joven Jorge 4, Camps Jordi 4, Castro Antoni 1, Pascual-Queralt Mercè 2
1 https://ror.org/04f7pyb58 Research Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
2 https://ror.org/04f7pyb58 Department of Urology Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
3 https://ror.org/04f7pyb58 Department of Clinical Laboratory Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
4 https://ror.org/04f7pyb58 Unitat de Recerca Biomèdica Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
Abstract
Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune®, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens.
Methods This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Urology
Receive our newsletter to stay up to date with the latest news in Urology